Zevra Therapeutics

Recent news

• Guggenheim Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Cuts Target Price to $23
  Market Newswire · 2026/8/7
• Rating change
  CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Cuts Target Price to $20
  Market Newswire · 2026/7/27
• H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $26
  Market Newswire · 2026/9/22
• Rating change
  CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $24
  Market Newswire · 2026/6/2
• Rating change
  A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $25 to $29
  Market Newswire · 2026/6/10
• Rating change
  Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $35
  Market Newswire · 2026/6/11
• Rating change
  A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $25 to $34
  Market Newswire · 2026/6/9
• Rating change
  A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $21 to $28
  Market Newswire · 2026/8/7
• Rating change
  Roth MKM Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $21
  Market Newswire · 2026/7/24
• Rating change
  BTIG Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Cuts Target Price to $24
  Market Newswire · 2026/7/27
• Rating change
  Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $35
  Market Newswire · 2026/8/8
• William Blair Initiates Zevra Therapeutics(ZVRA.US) With Buy Rating
  Market Newswire · 2026/10/1
• CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $20
  Market Newswire · 2026/8/12
• Rating change
  Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $25
  Market Newswire · 2026/5/9
• Company notice
  KemPharm: KemPharm, Inc. - Name/Symbol Change Option Symbol: KMPH New Symbol: ZVRA
  OCC · 2023/2/28
• Rating change
  CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $29
  Market Newswire · 2026/6/11
• Rating change
  BTIG Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $27
  Market Newswire · 2026/7/1
• Rating change
  A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $24 to $28
  Market Newswire · 2026/8/6
• Rating change
  William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating
  Market Newswire · 2026/7/25
• Zevra Therapeutics (ZVRA) Receives a Buy From H.C. Wainwright
  TipRanks · 2026/9/22

Headlines are aggregated automatically and are not independently verified or edited by our team.